Clinical Trials Logo

Depressive Disorder, Major clinical trials

View clinical trials related to Depressive Disorder, Major.

Filter by:

NCT ID: NCT05385783 Completed - Clinical trials for Major Depressive Disorder

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

Start date: August 2, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).

NCT ID: NCT05384405 Recruiting - Clinical trials for Major Depressive Disorder

aiTBS for Relieving NSSI in Depressive Patients

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

Repetitive transcranial magnetic stimulation (rTMS) has been successfully used to help patients with treatment resistant depression. However, its role in alleviating self injuries without suicidal ideation remained uncertain. This trial will compare the effectiveness of active accelerated intermittent theta burst stimulation (aiTBS) rTMS to a placebo control on non-suicidal self injury (NSSI) in patients with unipolar disorder and bipolar disorder.

NCT ID: NCT05384041 Completed - Clinical trials for Major Depressive Disorder

Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults

CES-MDD
Start date: April 28, 2022
Phase: N/A
Study type: Interventional

This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in adults.

NCT ID: NCT05381974 Withdrawn - Clinical trials for Treatment-Resistant Major Depressive Disorder

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

Start date: September 15, 2022
Phase: Phase 2
Study type: Interventional

This open-label fMRI study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with treatment-resistant major depressive disorder.

NCT ID: NCT05376150 Completed - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

X-NOVA
Start date: May 19, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.

NCT ID: NCT05366270 Recruiting - Clinical trials for Major Depressive Disorder

Peripheral Neuroimmune Mechanisms of Hyperthermia

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to examine how whole-body hyperthermia affects the thermoinflammatory profile, which includes the combined immune and heat shock response, in patients with depression and whether these changes correlate with decreased depression in individuals with Major Depressive Disorder.

NCT ID: NCT05357040 Recruiting - Clinical trials for Major Depressive Disorder

Antidepressant Effects of Nitrous Oxide

Start date: June 30, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and to plan a future large pragmatic trial.

NCT ID: NCT05355285 Completed - Clinical trials for Major Depressive Disorder

Type 1 Diabetes and Depression: Role of Brain Glutamate

Start date: January 2011
Phase: N/A
Study type: Interventional

The goal of this study is to examine the effect of chronic and acute hyperglycemia in type 1 diabetes mellitus (T1DM) on brain glutamate levels using magnetic resonance spectroscopy (MRS), and associations of brain glutamate with symptoms of depression.

NCT ID: NCT05353543 Not yet recruiting - Clinical trials for Major Depressive Disorder

Acupuncture Therapy Based on Biological Specificity of Acupoints for Major Depressive Disorder

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Acupoints are the stimulus points and reactive points for acupuncture to treat the diseases. Therefore, this study is designed to detect the biological specificity of acupoints in healthy participants and major depressive disorder (MDD) participants by using multiple objective assessment tools. And then acupoints that are statistically different between the two groups will be defined as strong reaction points, and other acupoints without statistically different will be defined as weak response points. In addition, this clinical trial will be conducted to explore whether the efficacy of stimulating strong reaction acupoints is more effective than weak reaction points, thereby confirming the specificity of the acupoint.

NCT ID: NCT05352113 Not yet recruiting - Clinical trials for Major Depressive Disorder

Intradermal Needle Therapy for Major Depressive Disorder

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Major depressive disorder (MDD) is a common mental disorder that affects patients' physical health and quality of life. Although traditional acupuncture therapy has certain advantages in improving MDD, there are still some limitations, such as being time-consuming and some people having a fear of acupuncture. Therefore, intradermal needle therapy will be chosen in the treatment of MDD in this study, which is more convenient, shallow needling, and gentle than traditional acupuncture therapy. The study is designed to investigate the therapeutic effect and safety of intradermal needles for MDD.